136 related articles for article (PubMed ID: 27743987)
21. New developments in the antiviral treatment of hepatitis C.
de Bruijne J; Weegink CJ; Jansen PL; Reesink HW
Vox Sang; 2009 Jul; 97(1):1-12. PubMed ID: 19392783
[TBL] [Abstract][Full Text] [Related]
22. Changes in liver histology as a "surrogate" end point of antiviral therapy for chronic HBV can predict progression to liver complications.
Hui CK; Leung N; Shek WH; Zhang HY; Luk JM; Poon RT; Lo CM; Fan ST; Lau GK;
J Clin Gastroenterol; 2008; 42(5):533-8. PubMed ID: 18344885
[TBL] [Abstract][Full Text] [Related]
23. [Cost-effectiveness analysis of sofosbuvir, peginterferon and ribavirin in patients with chronic hepatitis C: Early treatment in the initial stage of fibrosis vs. delayed treatment in advanced fibrosis].
Buti M; Domínguez-Hernández R; Oyagüez I; Casado MÁ
Gastroenterol Hepatol; 2016; 39(7):449-57. PubMed ID: 27084669
[TBL] [Abstract][Full Text] [Related]
24. HCC incidence after hepatitis C cure among patients with advanced fibrosis or cirrhosis: A meta-analysis.
Lockart I; Yeo MGH; Hajarizadeh B; Dore GJ; Danta M
Hepatology; 2022 Jul; 76(1):139-154. PubMed ID: 35030279
[TBL] [Abstract][Full Text] [Related]
25. Natural histories of hepatitis C virus infection in men and women simulated by the Markov model.
Tanaka J; Kumada H; Ikeda K; Chayama K; Mizui M; Hino K; Katayama K; Kumagai J; Komiya Y; Miyakawa Y; Yoshizawa H
J Med Virol; 2003 Jul; 70(3):378-86. PubMed ID: 12767000
[TBL] [Abstract][Full Text] [Related]
26. Impact of improved treatment on disease burden of chronic hepatitis C in New Zealand.
Gane E; Stedman C; Brunton C; Radke S; Henderson C; Estes C; Razavi H
N Z Med J; 2014 Dec; 127(1407):61-74. PubMed ID: 25530333
[TBL] [Abstract][Full Text] [Related]
27. Future complications of chronic hepatitis C in a low-risk area: projections from the hepatitis c study in Northern Norway.
Kileng H; Bernfort L; Gutteberg T; Moen OS; Kristiansen MG; Paulssen EJ; Berg LK; Florholmen J; Goll R
BMC Infect Dis; 2017 Sep; 17(1):624. PubMed ID: 28915795
[TBL] [Abstract][Full Text] [Related]
28. Prevalence and challenges of liver diseases in patients with chronic hepatitis C virus infection.
Jacobson IM; Davis GL; El-Serag H; Negro F; Trépo C
Clin Gastroenterol Hepatol; 2010 Nov; 8(11):924-33; quiz e117. PubMed ID: 20713178
[TBL] [Abstract][Full Text] [Related]
29. A clinician's guide to the cost and health benefits of hepatitis C cure assessed from the individual patient perspective.
McEwan P; Selvapatt N; Brown A; Thursz M; Bennett H; Webster S; Kalsekar A; Yuan Y; Brenner M; Gordon J
Eur J Gastroenterol Hepatol; 2017 Feb; 29(2):208-214. PubMed ID: 27832039
[TBL] [Abstract][Full Text] [Related]
30. Ultrasound elastography for fibrosis surveillance is cost effective in patients with chronic hepatitis C virus in the UK.
Canavan C; Eisenburg J; Meng L; Corey K; Hur C
Dig Dis Sci; 2013 Sep; 58(9):2691-704. PubMed ID: 23720196
[TBL] [Abstract][Full Text] [Related]
31. [Effects of IFN therapy on incidence of hepatocellular carcinoma in HCV positive cirrhosis].
Nishiguchi S; Kubo S; Shiomi S
Nihon Rinsho; 2004 Jul; 62 Suppl 7(Pt 1):600-4. PubMed ID: 15359868
[No Abstract] [Full Text] [Related]
32. Interferon-induced prolonged biochemical response reduces hepatocarcinogenesis in hepatitis C virus infection.
Arase Y; Ikeda K; Suzuki F; Suzuki Y; Kobayashi M; Akuta N; Hosaka T; Sezaki H; Yatsuji H; Kawamura Y; Kobayashi M; Kumada H
J Med Virol; 2007 Oct; 79(10):1485-90. PubMed ID: 17705189
[TBL] [Abstract][Full Text] [Related]
33. Impact of Fibroscan on management of chronic viral hepatitis in clinical practice.
Fransen van de Putte D; Blom R; van Soest H; Mundt M; Verveer C; Arends J; de Knegt RE; Mauser-Bunschoten E; van Erpecum K
Ann Hepatol; 2011; 10(4):469-76. PubMed ID: 21911887
[TBL] [Abstract][Full Text] [Related]
34. [Impact of antiviral therapy on the natural history of hepatitis C virus].
Fernández Rodriguez CM; Gutierrez Garcia ML
Gastroenterol Hepatol; 2014 Dec; 37(10):583-92. PubMed ID: 25066318
[TBL] [Abstract][Full Text] [Related]
35. Non-invasive fibrosis assessment predicts sustained virological response to telaprevir with pegylated interferon and ribavirin for chronic hepatitis C.
Ogawa E; Furusyo N; Shimizu M; Ihara T; Hayashi T; Harada Y; Toyoda K; Murata M; Hayashi J
Antivir Ther; 2015; 20(2):185-92. PubMed ID: 24941012
[TBL] [Abstract][Full Text] [Related]
36. Hepatitis C Virus-related chronic liver disease in elderly patients: an Italian cross-sectional study.
Gramenzi A; Conti F; Felline F; Cursaro C; Riili A; Salerno M; Gitto S; Micco L; Scuteri A; Andreone P; Bernardi M
J Viral Hepat; 2010 May; 17(5):360-6. PubMed ID: 19758274
[TBL] [Abstract][Full Text] [Related]
37. Future trends of HCV-related cirrhosis and hepatocellular carcinoma under the currently available treatments.
Sypsa V; Touloumi G; Papatheodoridis GV; Tassopoulos NC; Ketikoglou I; Vafiadis I; Hatzis G; Tsantoulas D; Akriviadis E; Koutsounas S; Hatzakis A
J Viral Hepat; 2005 Sep; 12(5):543-50. PubMed ID: 16108772
[TBL] [Abstract][Full Text] [Related]
38. Management of hepatitis C in decentralised versus centralised drug substitution programmes and minimally invasive point-of-care tests to close gaps in the HCV cascade.
Bregenzer A; Conen A; Knuchel J; Friedl A; Eigenmann F; Näf M; Ackle P; Roth M; Fux CA
Swiss Med Wkly; 2017; 147():w14544. PubMed ID: 29185250
[TBL] [Abstract][Full Text] [Related]
39. Changes in liver fibrosis in HIV/HCV-coinfected patients following different outcomes with peginterferon plus ribavirin therapy.
Labarga P; Fernandez-Montero JV; Barreiro P; Pinilla J; Vispo E; de Mendoza C; Plaza Z; Soriano V
J Viral Hepat; 2014 Jul; 21(7):475-9. PubMed ID: 24750394
[TBL] [Abstract][Full Text] [Related]
40. Natural history of hepatitis C virus infection: from chronic hepatitis to cirrhosis, to hepatocellular carcinoma.
Leone N; Rizzetto M
Minerva Gastroenterol Dietol; 2005 Mar; 51(1):31-46. PubMed ID: 15756144
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
